| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Yusaku Iwasaki, Chayon Goswami, Toshihiko Yad. Glucagon-like peptide-1 and insulin synergistically activate vagal afferent neurons. Neuropeptides. vol 65. 2018-06-14. PMID:28624122. |
however, whether the vagal afferents are involved in the interactive effects of glp-1 and insulin remains unknown. |
2018-06-14 |
2023-08-13 |
mouse |
| Yusaku Iwasaki, Chayon Goswami, Toshihiko Yad. Glucagon-like peptide-1 and insulin synergistically activate vagal afferent neurons. Neuropeptides. vol 65. 2018-06-14. PMID:28624122. |
the present study explored possible cooperative effect of glp-1 and insulin on vagal afferent neurons isolated from nodose ganglion (ng) of mice, while monitoring the neuronal activity by measuring cytosolic ca |
2018-06-14 |
2023-08-13 |
mouse |
| Faruk H Moonschi, Corey B Hughes, George M Mussman, John L Fowlkes, Chris I Richards, Iuliana Popesc. Advances in micro- and nanotechnologies for the GLP-1-based therapy and imaging of pancreatic beta-cells. Acta diabetologica. vol 55. issue 5. 2018-06-12. PMID:29264724. |
the incretin hormone glp-1 has powerful antihyperglycemic effect through direct stimulation of insulin biosynthesis and secretion within the β-cells; it normalizes β-cell sensitivity to glucose, has an antiapoptotic role, stimulates β-cell proliferation and differentiation, and inhibits glucagon secretion. |
2018-06-12 |
2023-08-13 |
Not clear |
| Juan Rosas-Guzman, Juan Rosas-Saucedo, Alma R J Romero-Garci. SGLT2 Inhibitors in Diabetes Mellitus Treatment. Reviews on recent clinical trials. vol 12. issue 1. 2018-06-11. PMID:27765008. |
t2dm physiopathology is very complex; insulin resistance in the muscle, liver, and adipose tissue, a reduction in the production of incretins (mainly glp-1) in the intestine, increased glucagon synthesis, an insufficient response of insulin generation, and increased glucose reabsorption in the kidney lead all together to an hyperglycemic state, which has been closely associated with the development of micro and macrovascular complications. |
2018-06-11 |
2023-08-13 |
Not clear |
| Ian Blumer, Jeremy H Pettus, Tricia Santos Cavaiol. Fixed-ratio combination therapy for type 2 diabetes: the top ten things you should know about insulin and glucagon-like peptide-1 receptor agonist combinations. Postgraduate medicine. vol 130. issue 4. 2018-06-11. PMID:29521173. |
combining basal insulin with a glucagon-like peptide-1 receptor agonist (glp-1 ra) for the treatment of patients with t2d has been demonstrated to be effective and well tolerated, while mitigating many of the adverse events associated with giving either of these drug classes alone. |
2018-06-11 |
2023-08-13 |
Not clear |
| Ian Blumer, Jeremy H Pettus, Tricia Santos Cavaiol. Fixed-ratio combination therapy for type 2 diabetes: the top ten things you should know about insulin and glucagon-like peptide-1 receptor agonist combinations. Postgraduate medicine. vol 130. issue 4. 2018-06-11. PMID:29521173. |
two titratable, fixed-ratio combination therapies, iglarlixi and ideglira, that combine basal insulin and a glp-1 ra in a once-daily subcutaneous injection are currently approved by the us food and drug administration (fda) for the treatment of patients with t2d. |
2018-06-11 |
2023-08-13 |
Not clear |
| H M de Wit, G M M Vervoort, B E de Galan, C J Tac. A cost-controlling treatment strategy of adding liraglutide to insulin in type 2 diabetes. The Netherlands journal of medicine. vol 75. issue 7. 2018-06-05. PMID:28956786. |
addition of the glp-1 receptor agonist liraglutide to insulin can reverse insulin-associated weight gain, improve hba1c and decrease the need for insulin, but is expensive. |
2018-06-05 |
2023-08-13 |
Not clear |
| Lesley J Scot. Insulin Glargine/Lixisenatide: A Review in Type 2 Diabetes. Drugs. vol 77. issue 12. 2018-06-01. PMID:28667587. |
subcutaneous insulin glargine/lixisenatide (suliqua™) is a titratable, fixed-ratio combination of a long-acting basal insulin analogue and a glucagon-like peptide-1 (glp-1) receptor agonist for the treatment of adult patients with inadequately controlled type 2 diabetes. |
2018-06-01 |
2023-08-13 |
Not clear |
| S Kaviani, J A Coope. Appetite responses to high-fat meals or diets of varying fatty acid composition: a comprehensive review. European journal of clinical nutrition. vol 71. issue 10. 2018-05-31. PMID:28098139. |
measures of appetite included visual analog scale (vas) questionnaires, appetite hormones (cholecystokinin (cck), glucagon-like peptide-1 (glp-1), peptide yy (pyy), gastric insulinotropic polypeptide gastric inhibitory peptide (gip), ghrelin, leptin, insulin) and/or energy intake (ei) data. |
2018-05-31 |
2023-08-13 |
human |
| Huili Zhu, Yusheng Zhang, Zhongshan Shi, Dan Lu, Tingting Li, Yan Ding, Yiwen Ruan, Anding X. The Neuroprotection of Liraglutide Against Ischaemia-induced Apoptosis through the Activation of the PI3K/AKT and MAPK Pathways. Scientific reports. vol 6. 2018-05-30. PMID:27240461. |
glucagon-like peptide-1 (glp-1) is an incretin hormone that increases glucose-dependent insulin secretion to reduce the glucose level. |
2018-05-30 |
2023-08-13 |
rat |
| Kohzo Takebayashi, Kenji Hara, Tomoko Terasawa, Rika Naruse, Mariko Suetsugu, Takafumi Tsuchiya, Toshihiko Inuka. Effect of canagliflozin on circulating active GLP-1 levels in patients with type 2 diabetes: a randomized trial. Endocrine journal. vol 64. issue 9. 2018-05-30. PMID:28824041. |
in conclusions, canagliflozin-administration before meals decreased pg and serum insulin, and increased plasma active glp-1 levels in patients with type 2 diabetes. |
2018-05-30 |
2023-08-13 |
Not clear |
| Lotta E Andersson, Liliya Shcherbina, Mahmoud Al-Majdoub, Neelanjan Vishnu, Claudia Balderas Arroyo, Jonathan Aste Carrara, Claes B Wollheim, Malin Fex, Hindrik Mulder, Nils Wierup, Peter Spége. Glutamine-Elicited Secretion of Glucagon-Like Peptide 1 Is Governed by an Activated Glutamate Dehydrogenase. Diabetes. vol 67. issue 3. 2018-05-25. PMID:29229616. |
glucagon-like peptide 1 (glp-1), secreted from intestinal l cells, glucose dependently stimulates insulin secretion from β-cells. |
2018-05-25 |
2023-08-13 |
mouse |
| Lotta E Andersson, Liliya Shcherbina, Mahmoud Al-Majdoub, Neelanjan Vishnu, Claudia Balderas Arroyo, Jonathan Aste Carrara, Claes B Wollheim, Malin Fex, Hindrik Mulder, Nils Wierup, Peter Spége. Glutamine-Elicited Secretion of Glucagon-Like Peptide 1 Is Governed by an Activated Glutamate Dehydrogenase. Diabetes. vol 67. issue 3. 2018-05-25. PMID:29229616. |
both dmg and glutamine alone elicited glp-1 secretion in glutag cells and in vivo, whereas activation of glutamate dehydrogenase (gdh) was required to stimulate insulin secretion from ins-1 832/13 cells. |
2018-05-25 |
2023-08-13 |
mouse |
| Lotta E Andersson, Liliya Shcherbina, Mahmoud Al-Majdoub, Neelanjan Vishnu, Claudia Balderas Arroyo, Jonathan Aste Carrara, Claes B Wollheim, Malin Fex, Hindrik Mulder, Nils Wierup, Peter Spége. Glutamine-Elicited Secretion of Glucagon-Like Peptide 1 Is Governed by an Activated Glutamate Dehydrogenase. Diabetes. vol 67. issue 3. 2018-05-25. PMID:29229616. |
metabolism of glutamine and related analogs by gdh in the l cell may explain why glp-1 secretion, but not that of insulin, is activated by these secretagogues in vivo. |
2018-05-25 |
2023-08-13 |
mouse |
| Teresa Buenaventura, Nisha Kanda, Phoebe C Douzenis, Ben Jones, Stephen R Bloom, Pauline Chabosseau, Ivan R Corrêa, Domenico Bosco, Lorenzo Piemonti, Piero Marchetti, Paul R Johnson, A M James Shapiro, Guy A Rutter, Alejandra Toma. A Targeted RNAi Screen Identifies Endocytic Trafficking Factors That Control GLP-1 Receptor Signaling in Pancreatic β-Cells. Diabetes. vol 67. issue 3. 2018-05-25. PMID:29284659. |
we identify five (clathrin, dynamin1, ap2, sorting nexins [snx] snx27, and snx1) that increase and four (huntingtin-interacting protein 1 [hip1], hip14, gasp-1, and nedd4) that decrease insulin secretion from murine insulinoma min6b1 cells in response to the glp-1 analog exendin-4. |
2018-05-25 |
2023-08-13 |
mouse |
| Enkhjargal Tsend-Ayush, Chuan He, Mark A Myers, Sof Andrikopoulos, Nicole Wong, Patrick M Sexton, Denise Wootten, Briony E Forbes, Frank Grutzne. Monotreme glucagon-like peptide-1 in venom and gut: one gene - two very different functions. Scientific reports. vol 6. 2018-05-24. PMID:27898108. |
the importance of glucagon like peptide 1 (glp-1) for metabolic control and insulin release sparked the evolution of genes mimicking glp-1 action in venomous species (e.g. |
2018-05-24 |
2023-08-13 |
Not clear |
| Enkhjargal Tsend-Ayush, Chuan He, Mark A Myers, Sof Andrikopoulos, Nicole Wong, Patrick M Sexton, Denise Wootten, Briony E Forbes, Frank Grutzne. Monotreme glucagon-like peptide-1 in venom and gut: one gene - two very different functions. Scientific reports. vol 6. 2018-05-24. PMID:27898108. |
we also show that monotreme glp-1 stimulates insulin release in cultured rodent islets, but surprisingly shows low receptor affinity and bias toward erk signaling. |
2018-05-24 |
2023-08-13 |
Not clear |
| Xiaofei Huang, Sha Li, Mei Yang, Xuquan Fu, Huaqi Li, Tong Yan, Yidong Liu, Lihong Chen, Lingsheng Lan, Libo Li, Xiaowei Zhon. The effects of short-term continuous subcutaneous insulin infusion treatment on fasting glucagon-like peptide-1 concentrations in newly diagnosed type 2 diabetes. Diabetes research and clinical practice. vol 138. 2018-05-24. PMID:29408704. |
we did a study to observe the changes of glp-1 and β-cell function after short-term continuous subcutaneous insulin infusion (csii) treatment. |
2018-05-24 |
2023-08-13 |
Not clear |
| Zachary Bloomgarde. Is insulin the preferred treatment for HbA1c >9%? Journal of diabetes. vol 9. issue 9. 2018-05-07. PMID:28589542. |
rather, studies comparing basal insulin directly with glucagon-like peptide-1 (glp-1) receptor agonists (ra) suggest that the latter agents may offer superior benefit. |
2018-05-07 |
2023-08-13 |
human |
| Dominic N McBrayer, Yftah Tal-Ga. Recent Advances in GLP-1 Receptor Agonists for Use in Diabetes Mellitus. Drug development research. vol 78. issue 6. 2018-05-07. PMID:28786125. |
preclinical research mimetics of glucagon-like peptide 1 (glp-1) represent a useful alternative or complementary treatment choice to insulin in the treatment of diabetes mellitus. |
2018-05-07 |
2023-08-13 |
Not clear |